Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DelVIN: VTD-101 in VIN 2/3
NCT05717621Phase 1Completed
- Sponsor
- ViMREX GmbH
- Start
- Mar 2023
- Primary completion
- Jan 2025
- Modality
- Transdermal Patches, Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of decitabine ointment in vulvar intraepithelial neoplasia (VIN), sponsored by ViMREX GmbH. Primary endpoints: Recommended Phase 2 Dose - Safety/Tolerability at 28 days and Recommended Phase 2 Dose - Efficacy at 16 months. Started Mar 2023; status: completed.
02
Drugs
decitabine ointment
03
Conditions
vulvar intraepithelial neoplasia (VIN)
Beyond the preview
Go deeper on NCT05717621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05717621.